http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112213488-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4d4b72c40acdad914a1981302716e2f7 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57492 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-577 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-577 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate | 2018-11-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_564834963e25b16eed49a896279670a5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12495d707c0bb7501356dbb9a61752e8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_75c9958bbf7dff88a084ef743b6ca1de |
| publicationDate | 2021-01-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-112213488-A |
| titleOfInvention | Application of PL2L60 protein in preparation of kit for early screening or diagnosis of tumor |
| abstract | The invention relates to the technical field of medicines, provides application of PL2L60 protein as a tumor diagnosis marker, and particularly relates to application of PL2L60 protein in preparation of a kit for early screening or diagnosis of tumors, wherein a tumor screening or diagnosis reagent refers to a reagent for screening or diagnosis of tumor stem cells or tumor progenitor cells, and the tumors refer to leukemia, lymphoma, breast cancer, cervical cancer, lung cancer, pancreatic cancer, colon cancer or liver cancer. Research results show that the PL2L60 protein has tumor specificity and tumor broad spectrum, particularly has specific expression on the surface of tumor stem/progenitor cells, takes PL2L60 as a target, not only can research and develop high-efficiency antibody drugs, cell therapy technology and tumor vaccines, but also can research and develop early tumor diagnosis reagents, contributes to the progress of tumor diagnosis and treatment, is beneficial to promoting clinical tumor immunotherapy, and has wide clinical application prospect. |
| priorityDate | 2018-11-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 20.